Vulvar Cancer Awareness Day: Vaccination

Elmar A. Joura
Medical University of Vienna - Comprehensive Cancer Center
Department of Gynecologic Oncology

Torino, 18. September 2019
HPV types in vulvar cancer

- HPV 16: 60%
- HPV 33: 29%
- HPV 18: 4.90%
- HPV 6/11: 2.2%
- Other HPV: 2%
- HPV -: 1.6%
## Anti-HPV 16/18 Efficacy – Comparison with the Placebo Cohort of the qHPV Vaccine Program

### Supportive Analysis – Per Protocol Efficacy Population

<table>
<thead>
<tr>
<th></th>
<th>V503</th>
<th>FUTURE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9vHPV</td>
<td>qHPV</td>
</tr>
<tr>
<td>n</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>HPV 16/18-related LSIL</td>
<td>0 / 5715</td>
<td>2 / 5732</td>
</tr>
<tr>
<td>HPV 16/18-related HSIL+</td>
<td>1 / 5715</td>
<td>0 / 5732</td>
</tr>
<tr>
<td>HPV 16/18-related H- VIN or VaIN</td>
<td>0 / 5762</td>
<td>2 / 5789</td>
</tr>
</tbody>
</table>
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women


ABSTRACT

BACKGROUND
The investigational 9-valent viruslike particle vaccine against human papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6, 11, 16, and 18) and five additional oncogenic types (31, 33, 45, 52, and 58). Here we present the results of a study of the efficacy and immunogenicity of the 9vHPV vaccine in women 16 to 26 years of age.

METHODS

The authors' full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Joura at the Department of Gynecology and Obstetrics, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, Austria, or at elmar.joura@meduniwien.ac.at.
HPV 31/33/45/52/58 Vaccine Efficacy

Per-Protocol Efficacy Population- end of study

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>9vHPV (n)</th>
<th>qHPV (n)</th>
<th>Vaccine Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>All CIN</td>
<td>2 / 5949</td>
<td>110 / 5943</td>
<td>98.2% (93.7, 99.7)</td>
</tr>
<tr>
<td>&gt; CIN2</td>
<td>1 / 5949</td>
<td>35 / 5943</td>
<td>97.1% (83.5, 99.9)</td>
</tr>
<tr>
<td>&gt; CIN3</td>
<td>0 / 5949</td>
<td>7 / 5,943</td>
<td>100% (39.4, 100)</td>
</tr>
<tr>
<td>All VIN, VaIN</td>
<td>1 / 6009</td>
<td>18 / 6012</td>
<td>94.4% (67.7, 99.7)</td>
</tr>
<tr>
<td>&gt; H- VIN, VaIN</td>
<td>0 / 6009</td>
<td>3 / 6012</td>
<td>100.0% (-71.5, 100)</td>
</tr>
</tbody>
</table>
Number needed to vaccinate (NNV)
Nonavalente HPV VAccine

- Cancer <100
- Precancer <10
- Genital warts <10
- Any HPV-disease 4

Girls, France
13th Congress of the ECSVD
European College for the Study of Vulva Disease
September 10 - 12, 2020
Vienna, Austria

www.ecsvd.eu